ArticleScientific reports2026
Integrated metabolomic, cytotoxic, and computational investigation of Caralluma tuberculata extract in breast cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caralluma tuberculata, belonging to the family Apocynaceae, is widely used in folk medicine for the management of diseases such as diabetes and cancer, owing to its rich secondary metabolite profile. This study aimed to explore the metabolites of C. tuberculata and evaluate their anti-breast cancer activity using high-performance liquid chromatography (HPLC), Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS), and the MTT assay. HPLC and LC-ESI-MS/MS analyses revealed major bioactive peaks at 17-22 and 45-80 min, indicating a high diversity of phytoconstituents. Metabolomic analysis identified 60 phytochemicals, highlighting the plant as a rich source of compounds with potential pharmacological relevance. Moreover, the extract exhibited selective cytotoxicity against MDA-MB-231 breast cancer cells (44% reduction in viability) while exerting comparatively lower effects on non-tumorigenic MCF-12F breast cells (22%), suggesting its potential as a source of bioactive compounds. To explore potential molecular targets associated with these effects, the identified metabolites were evaluated for their interactions with carnitine palmitoyltransferase 1A (CPT1A) using molecular docking. Among them, diosmetin and luteolin showed the strongest binding affinities and favorable safety profiles. Molecular dynamics simulations of these selected compounds further supported the stability of their interactions with CPT1A. These findings highlight diosmetin and luteolin as promising candidates for further investigation as potential modulators of CPT1A in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.